866-997-4948(US-Canada Toll Free)

Talactoferrin Alfa (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 34 Pages

 

GlobalDatas pharmaceuticals report, Talactoferrin Alfa (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020 provides Talactoferrin Alfa sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Talactoferrin Alfa including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Talactoferrin Alfa including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2002-2020 for Talactoferrin Alfa in the US, EU-5, Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Pipeline Report Guidance 8


3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11
3.3.6 12


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12


5 Talactoferrin Alfa 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Factors Affecting Sales of Talactoferrin Alfa 16
5.4.1 NSCLC Market 16
5.4.2 Fast Track Designation 16
5.4.3 High Efficacy 17
5.4.4 Low Toxicity Profile 17
5.4.5 Larger Patient Pool 17
5.4.6 Oral Administration 17
5.5 Drug Risk Benefit Score 17
5.5.1 Efficacy 17
5.5.2 Safety 18
5.5.3 Compliance 18
5.5.4 Dosing Convenience 18
5.6 Intensity of Competition 18
5.7 Sales forecast 18
5.7.1 Target patient Pool of Talactoferrin Alfa 18
5.7.2 Dosing 19
5.7.3 Market Penetration 19
5.7.4 Annual Cost of Therapy 20
5.7.5 Sales Projections of Talactoferrin Alfa 20


6 NSCLC Market: Appendix 29
6.1 Market Definitions 29
6.2 Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 31
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 33
6.3.8 Primary Research 33
6.3.9 Expert Panels 33
6.4 Contact Us 33
6.5 Disclaimer 33
6.6 Sources 34

List of Table


1.1 List of TablesTable 1: NSCLC, Incidences and Mortality, 20082030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3: Drug Risk Benefit Score of Talactoferrin Alfa 17
Table 4: Talactoferrin Alfa, NSCLC, Global Sales Forecast ($m), 20122020 20
Table 5: Talactoferrin Alfa, NSCLC, The US, Sales Forecast ($m), 20122020 21
Table 6: Talactoferrin Alfa, NSCLC, The UK, Sales Forecast ($m), 20122020 22
Table 7: Talactoferrin Alfa, NSCLC, France, Sales Forecast ($m), 20122020 23
Table 8: Talactoferrin Alfa, NSCLC, Germany, Sales Forecast ($m), 20122020 24
Table 9: Talactoferrin Alfa, NSCLC, Italy, Sales Forecast ($m), 20122020 25
Table 10: Talactoferrin Alfa, NSCLC, Spain, Sales Forecast ($m), 20122020 26
Table 11: Talactoferrin Alfa, NSCLC, Japan, Sales Forecast ($m), 20142020 27

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: Oncology, Global, Incidence (in million), 2008-2030 10
Figure 8: NSCLC, Global, Incidence (in million), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Clinical Studies of Talactoferrin Alfa 16
Figure 13: Drug Model Diagram of Talactoferrin Alfa 18
Figure 14: Talactoferrin Alfa, NSCLC, Global Sales Forecast ($m), 20122020 20
Figure 15: Talactoferrin Alfa, NSCLC, The US, Sales Forecast ($m), 20122020 21
Figure 16: Talactoferrin Alfa, NSCLC, The UK, Sales Forecast ($m), 20122020 22
Figure 17: Talactoferrin Alfa, NSCLC, France, Sales Forecast ($m), 20122020 23
Figure 18: Talactoferrin Alfa, NSCLC, Germany, Sales Forecast ($m), 20122020 24
Figure 19: Talactoferrin Alfa, NSCLC, Italy, Sales Forecast ($m), 20122020 25
Figure 20: Talactoferrin Alfa, NSCLC, Spain, Sales Forecast ($m), 20122020 26
Figure 21: Talactoferrin Alfa, NSCLC, Japan, Sales Forecast ($m), 20142020 27
Figure 22: Talactoferrin Alfa, NSCLC, Sales Forecast by Country ($m), 2020 28
Figure 23: GlobalData Methodology 30
Figure 24: Drug Model Diagram 32
Figure 25: Patients Approved for the Drug 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *